Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants
Zonglin Li(Peking University), Linong Ji(Peking University), Suiyuan Hu(Peking University), Wenjia Yang(Peking University), Chu Lin(Peking University), Jinyu Zhou(Peking University), Fang Lv(Liaoning Normal University), Xingyun Zhu(Peking University), Xiaoling Cai(Peking University)
Cited by 11
Related Papers
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses
|Diabetologia|2020|373
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
|Nature Medicine|2024|152
Luteolin-loaded solid lipid nanoparticles synthesis, characterization, & improvement of bioavailability, pharmacokinetics in vitro and vivo studies
|Journal of Nanoparticle Research|2014|128